Transgene, NEC and BostonGene extend collaboration for head and neck cancer vaccine
Biotech company Transgene, IT solutions provider NEC, and biomedical software company BostonGene have expanded their collaboration for the phase 1/2 trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers.
